Amphotericin B Plasma Monitoring for One Burn Child Using High-Performance Liquid Chromatography
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
Autores
SANCHES-GIRAUD, Cristina
CAMPOS, Edvaldo V.
PEREZ, Grazziela S.
SANTOS, Silvia R. C. J.
Citação
LATIN AMERICAN JOURNAL OF PHARMACY, v.30, n.8, p.1468-1474, 2011
Resumo
A bioanalytical micromethod was described for the quantification of amphotericin B in plasma by HPLC. The method showed high absolute recovery, good linearity (0.1-10.0 mu g/mL, r(2) = 0.999), sensitivity (limits of quantification: 0.1 mu g/mL), and acceptable stability. Inter/intraday precisions were 6.8 %/23 % and mean accuracy was 94.3 %. The method was applied to plasma monitoring of one burn child, 3 years old, 25 kg, thermal injury (18 % total burn surface area - TBSA). Amphotericin B (1 mg/kg) was prescribed from 24(tg) to 35(tg) day of the accident and plasma monitoring and pharmacokinetics was performed by serial blood collections on 274 and 354 days post burn. Plasma concentrations obtained were respectively 0.7 mu g/mL and 1.2 mu g/mL. Pharmacokinetics at both periods (27(tg) vs 35(tg) day) also was compared: 13.8 vs 14.3 h (t(1/2 beta)); 0.5 vs 03 mL/min.kg (CL(T)) and 0.65 vs 038 L/kg (Vd(ss)). In conclusion, drug plasma monitoring by HPLC was quite useful to guarantee low risk and drug efficacy in a paediatric burn patient.
Palavras-chave
Amphotericin B, Burn child, Drug plasma monitoring, HPLC-UV, Pharmacokinetics
Referências
- Italia JL, 2009, ANAL CHIM ACTA, V634, P110, DOI 10.1016/j.aca.2008.12.006
- Watt K, 2011, EARLY HUM DEV, V87, pS61, DOI 10.1016/j.earlhumdev.2011.01.014
- Espada R, 2008, BIOMED CHROMATOGR, V22, P402, DOI 10.1002/bmc.947
- GALLIS HA, 1990, REV INFECT DIS, V12, P308
- Andes D, 2006, INFECT DIS CLIN N AM, V20, P679, DOI 10.1016/j.idc.2006.06.007
- Blanchet B, 2008, CLIN PHARMACOKINET, V47, P635, DOI 10.2165/00003088-200847100-00002
- BENSON JM, 1989, ANTIMICROB AGENTS CH, V33, P1989
- Nath CE, 2001, BRIT J CLIN PHARMACO, V52, P671, DOI 10.1046/j.0306-5251.2001.01496.x
- Eldem T, 2001, J PHARMACEUT BIOMED, V25, P53, DOI 10.1016/S0731-7085(00)00499-4
- Antachopoulos C, 2006, J CLIN MICROBIOL, V44, P553, DOI 10.1128/JCM.44.2.553-560.2006
- BACH PR, 1984, ANTIMICROB AGENTS CH, V26, P314
- Catalan Mercedes, 2006, Revista Iberoamericana de Micologia, V23, P39
- Cleary JD, 2007, J ANTIMICROB CHEMOTH, V60, P1331, DOI 10.1093/jac/dkm322
- Echevarria I, 1998, J CHROMATOGR A, V819, P171, DOI 10.1016/S0021-9673(98)00425-7
- Egger P, 2001, J CHROMATOGR B, V760, P307, DOI 10.1016/S0378-4347(01)00292-4
- FDA Home page, 2008, GUID IND BIOAN METH
- GRANICH GG, 1986, ANTIMICROB AGENTS CH, V29, P584
- Guszecki W.I, 2002, FEBS LETT, V524, P92
- HOSOTSUBO H, 1988, ANTIMICROB AGENTS CH, V32, P1103
- HOSOTSUBO H, 1989, J PHARMACEUT BIOMED, V7, P975, DOI 10.1016/0731-7085(89)80022-6
- Lambros MP, 1996, J CHROMATOGR B, V685, P135
- LopezGalera R, 1995, J CHROMATOGR B, V674, P298, DOI 10.1016/0378-4347(95)00322-3
- Nath CE, 2007, CHEMOTHERAPY, V53, P142, DOI 10.1159/000100013